Search Results for "Caribou Biosciences (CRBU): Q2 2023 earnings. Predictable and steady. Blue-chip in the making."

Caribou Biosciences (CRBU): Q2 2023 earnings. Predictable and steady. Blue-chip in the making.

Caribou Biosciences on Fast Track to Cure Cancer

CARIBOU BIOSCIENCES INC SHARP PRICE MOVEMENT | CRBU STOCK

Caribou - Abbvie deal terminated- what this means for CRBU?

The Promise of Genome Editing with Caribou Biosciences' Rachel Haurwitz, Ph.D.

Editas Medicine: Earnings beat, sharp focus on spending and cash runway to 2025 - Earnings review.

Editas Drops EDIT-103 and iNK Cell Programs: Pipeline Reprioritization and Investor Concerns

Beam Q2 2023 - Slow & Steady.

⛔️TIME FOR JEROME POWELL TO CRASH THE STOCK MARKET? WHAT YOU NEED TO KNOW NOW!

Intellia has a special request from FDA for their NTLA-2002. Must know this if you hold NTLA.

Ginkgo Bioworks CEO: Our AI model will learn to speak DNA just like ChatGPT learned English

Palantir Stock & Israel Hamas Attack BREAKING News!